



Info: info@igbamedicines.org

Global Biosimilars Week 2026 Launches: Realizing the Global Value of Biosimilars

For immediate release

Geneva, 19 October 2026

Today marks the launch of Global Biosimilars Week 2026, running from 19-24 October, an online, international awareness campaign led by the International Generic and Biosimilar Medicines Association (IGBA). This year's theme, **"Realizing the Global Value of Biosimilars,"** aims to expand understanding of the powerful and life-changing impact biosimilar medicines can have for patients, healthcare systems, economies and societies around the world.

Biosimilar medicines are poised to infuse immense value into healthcare ecosystems across the globe, yet current regulatory, policy and legal constraints are delaying biosimilar entry in many markets. These delays limit patient access to cost-effective treatment options and can hold back healthcare innovation and economic growth. Global Biosimilars Week highlights the multiple dimensions of value that biosimilars can deliver and emphasizes the urgency for widespread education, resource sharing and purposeful policy, legal and regulatory reform.

"As the global community looks ahead to the 2027 United Nations General Assembly High-Level Meeting on Universal Health Coverage, the ambition to ensure accessible healthcare for everyone, everywhere has never been more important," said **Ana Gaunt, Secretary General of IGBA**. "Biosimilar medicines can be an important tool to deliver on that ambition. By expanding patient access to quality-assured, cost-effective treatments, biosimilars will help health systems make better use of limited resources while strengthening resiliency and improving health outcomes. Realizing the global value of biosimilar medicines means ensuring all patients, wherever they live, benefit from the improved health outcomes biosimilar medicines make possible."

As the global burden of non-communicable diseases rises, ensuring timely and sustainable access to biosimilar medicines is paramount. With **more than 1,000 biosimilar development programmes currently active globally**, the sector is working diligently to meet future healthcare needs. Expanding availability of cost-effective and quality-assured medicines, especially in low- and middle-income countries (LMICs), will positively impact patients needing complex therapeutic treatments and strengthen economies.

"The value of biosimilars cannot be measured by patient savings alone," said **Jim Keon, Chair of IGBA**. "We know biosimilar medicines are capable of expanding access to life-saving treatments, strengthening health systems, supporting economic resilience and generally improving lives. Global Biosimilars Week 2026 is about recognising these multiple dimensions of value and raising our collective voice, globally, to ensure patients and communities see the tangible benefits of that value."



During **Global Biosimilars Week 2026**, IGBA will bring together stakeholders from across healthcare, policy, industry and patient communities to share real-world experiences on [social media](#), while exploring the future of biosimilar medicines.

Attend the official Global Biosimilars Week Webinar: **Value of Global Access: The Benefits of Prioritizing Biosimilars** on 21 October 2026, from 08:00–09:30 EDT / 14:00–15:30 CEST – [Register Here](#).

Moderated by the Association for Accessible Medicines Senior VP of Sciences and Regulatory Affairs, and IGBA Biosimilar Committee Co-Chair, Giuseppe Randazzo, and featuring panellists from diverse global regions, the Global Biosimilars Week 2026 webinar will showcase real-world case studies and robust conversation around how the prioritization of biosimilars will expand patient access, generate sustainable value and strengthen healthcare systems around the world.

Media Contact

Visit www.globalbiosimilarsweek.org and www.igbamedicines.org

Follow the hashtag **#GlobalBiosimilarsWeek** on social media

Follow the IGBA LinkedIn: [igba-international-generic-and-biosimilars-association](https://www.linkedin.com/company/igba-international-generic-and-biosimilars-association)

Questions? Contact us through this [Form](#)

[Thanks to all our Media Partners](#)



About IGBA: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients' access to quality assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org